Business
HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
Patent continues to strengthen and expand IP portfolio Southlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences
About this update from Heartsciences Inc.
[{"type":"text","content":"Patent continues to strengthen and expand IP portfolio\nSouthlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for ECG quantification of echocardiographic measures of diastolic function of the heart using AI methods. Diastolic dysfunction (impaired cardiac relaxation) is an important indicator of overall heart health as it is impaired by all of the common pathological processes of heart disease and is a sensitive indicator of cardiovascular dysfunction. Diastolic dysfunction is recognized as one of the earliest signs of heart disease and typical onset occurs when a patient is still asymptomatic. Today, diastolic function of the heart must be assessed in a specialist cardiology environment typically using echocardiography-based imaging. Historically, ECGs have had limited, if any, role in the evaluation of cardiac dysfunction and, therefore, the ability to assess cardiac diastolic function using an ECG would make it a far more valuable cardiac screening tool particularly in frontline or point-of-care clinical settings. HeartSciences’ first device, the MyoVista® Wavelet ECG (wavECG™) leverages AI machine learning to detect cardiac dysfunction that cannot be diagnosed by current conventional ECGs. Its first algorithm is designed to provide diagnostic information related to impaired cardiac relaxation associated with diastolic dysfunction as well as all conventional ECG information in a single test. Andrew Simpson, Chief Executive Officer of HeartSciences, stated, “The ECG is a ubiquitous, relatively low-cost, simple and quick test that can be performed in a wide range of clinical settings by a non-specialist clinician or clinical aide. One of the most significant needs in healthcare is the ability to detect cardiac dysfunction early. Adding diagnostic information related to cardiac dysfunction to an ECG would not only make it a far more valuable cardiac screening tool, but also addresses a significant unmet need ...